Stage at presentation and survival outcomes of patients with Gleason 8–10 prostate cancer and low prostate-specific antigen
- 1 March 2016
- journal article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 34 (3) , 119.e19-119.e26
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Association of DSC3 mRNA Down-Regulation in Prostate Cancer with Promoter Hypermethylation and Poor PrognosisPLOS ONE, 2014
- Prevalence of the
HOXB13
G84E prostate cancer risk allele in men treated with radical prostatectomyBJU International, 2013
- Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsiesBMC Genomics, 2013
- Comparative analysis of prostate‐specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study GroupBJU International, 2012
- Outcomes in patients with Gleason score 8–10 prostate cancer: relation to preoperative PSA levelBJU International, 2011
- The impact of prostate‐specific antigen level at diagnosis on the relative survival of 28,531 men with localized carcinoma of the prostateCancer, 2008
- Prostate cancer progression in the presence of undetectable or low serum prostate‐specific antigen levelCancer, 2007
- Preoperative PSA and progression-free survival after radical prostatectomy for Stage T1c diseaseUrology, 2005
- Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostateUrology, 2003